Journal article
NET models meeting 2024: the current state of neuroendocrine tumour research models and our future aspirations
Endocrine oncology, Vol.4(1), e240055
11/19/2024
DOI: 10.1530/EO-24-0055
PMCID: PMC11737514
PMID: 39822778
Abstract
Current models for the study of neuroendocrine tumours (NETs) are severely limited. While in vitro (e.g. cell lines), ex vivo (e.g. organoids), and in vivo (e.g. mice) models all exist, each has limitations. To address these limitations and collectively identify strategies to move the NET models field forward, we held an inaugural NET Models meeting, hosted by our founding group: Dr. Lines (Oxford); Prof. Quelle (Iowa); Dr. Dayton (Barcelona); Dr. Ear (Iowa); Dr. Marinoni (Bern); and Dr. Guenter (Alabama). This 2-day meeting in Oxford (UK) was organised and supported by Bioscientifica Ltd and was solely dedicated to the discussion of NET models. The meeting was attended by 30 international researchers (from UK, EU, Israel, USA and Canada). Plenary talks were given by Prof. Thakker who summarised NET research over the last few decades, and Dr. Schrader who described the process and pitfalls of generating new cell lines. Eight researchers also presented their work on topics ranging from human cell 3D bioprinting, to zebrafish models, and included novel ideas as well as improvements on current concepts. This was followed by an interactive workshop where discussion topics included, a summary of currently available NET models, limitations of these models, barriers to developing new models, and how we can address these issues going forward. This white paper summarises the key points raised in these discussions, as well as the future aspirations of the NET Models Consortium. The next meeting will take place in Oxford (UK) in 2025, contact contact@netcancerfoundation.com for more information.
Details
- Title: Subtitle
- NET models meeting 2024: the current state of neuroendocrine tumour research models and our future aspirations
- Creators
- Po Hien Ear - University of IowaIlaria Marinoni - University of BernTalya Dayton - European Molecular Biology LaboratoryRachael Guenter - University of Alabama at BirminghamDawn Quelle - University of IowaAnna Battistella - IRCCS Ospedale San RaffaeleFloryne O Buishand - Royal Veterinary CollegeSuganthi Chittaranjan - S Chittaranjan, Department of Genome Sciences centre, BC Cancer - Vancouver, Vancouver, CanadaYi-Cheih Nancy Du - Cornell UniversityInes Marques - University of BernNatalia Pellegata - University of PaviaSamira Mercedes Sadowski - National Institutes of HealthAmit Tirosh - Sheba Medical CenterSimon April-Monn - University Hospital of ZurichCinzia Aurilia - C Aurilia, Associazione Italiana Neoplasie Endocrine Multiple di tipo 1 e di tipo 2 (AIMEN 1 e 2), Italy, ItalyRenata Jaskula-Sztul - University of Alabama at BirminghamMaria Jesús Baena Moreno - Research Institute Hospital 12 de OctubreSimone Donati - S Donati , Associazione Italiana Neoplasie Endocrine Multiple di tipo 1 e di tipo 2 (AIMEN 1 e 2), Italy, ItalyKatherine A English - University of OxfordMaria A. Hernandez Llorens - Research Institute Hospital 12 de OctubreHarry Hodgetts - University College LondonFrancesca Marini - Fondazione FADOIMaria Martins - University College LondonGaia Palmini - Florence (Netherlands)Beatriz Soldevilla - Research Institute Hospital 12 de OctubreJörg Schrader - University Medical Center Hamburg-EppendorfRajesh V Thakker - Oxford Centre for Diabetes, Endocrinology and MetabolismKate E Lines - Oxford Centre for Diabetes, Endocrinology and Metabolism
- Resource Type
- Journal article
- Publication Details
- Endocrine oncology, Vol.4(1), e240055
- DOI
- 10.1530/EO-24-0055
- PMID
- 39822778
- PMCID
- PMC11737514
- NLM abbreviation
- Endocr Oncol
- ISSN
- 2634-4793
- eISSN
- 2634-4793
- Language
- English
- Electronic publication date
- 11/2024
- Date published
- 11/19/2024
- Academic Unit
- Pathology; Surgery; Neuroscience and Pharmacology
- Record Identifier
- 9984749733302771
Metrics
11 Record Views